Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Our top ASX picks in every sector
stocks
Potentially catastrophic ruling for ASX company
stocks
4 charts on Nvidia’s record $4 trillion market cap
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,852.10 | 36.80 | 0.42% |
CAC 40 | 7,808.17 | 21.12 | -0.27% |
DAX 40 | 24,160.64 | 94.67 | -0.39% |
Dow JONES (US) | 44,459.65 | 88.14 | 0.20% |
FTSE 100 | 8,998.06 | 56.94 | 0.64% |
HKSE | 24,203.32 | 63.75 | 0.26% |
NASDAQ | 20,640.33 | 54.80 | 0.27% |
Nikkei 225 | 39,446.09 | 13.53 | -0.03% |
NZX 50 Index | 12,676.16 | 2.53 | -0.02% |
S&P 500 | 6,268.56 | 8.81 | 0.14% |
S&P/ASX 200 | 8,609.00 | 38.60 | 0.45% |
SSE Composite Index | 3,519.65 | 9.47 | 0.27% |